System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Adam Brufsky is an expert in Oncology at University of Pittsburgh Medical Center (United States). As of October 2026, ScienceLeadR ranks Adam Brufsky in the top 1% of experts worldwide for Breast Neoplasms, Breast Diseases and Artificial Intelligence. Adam Brufsky has authored 781 publications, the most recent in 2026, and is an investigator in 51 clinical trials, 7 of them ongoing. SLR score: 3,629 (community average: 125). How the SLR is computed.

LeadR Profile

Adam Brufsky University of Pittsburgh Medical Center United States
3 629 ScienceLeadR Reputation 3629

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pharmacy - Dermatology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1990 - 2026
Source: PubMed

University of Pittsburgh

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 781

Citations

Citations: 51 568 1st author: 92 Last author: 139 Unique author: 23

Main journals

J Clin Oncol 146
Cancer Res 144
Ann Oncol 42
Breast Cancer Res Treat 25
Clin Cancer Res 22

Best Journals

J Clin Oncol 48
Ann Oncol 30
N Engl J Med 17

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer.
PMID 42907427 — genes, breast neoplasms, neoplasms, breast, alleles, therapeutics		Nat Commun20260
Clinical Utility of [ 18F]Fluoroestradiol PET/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy.
PMID 42892305 — breast neoplasms, neoplasms, positron emission tomography computed tomography, breast, therapeutics, wounds and injuries		Clin Breast Cancer20260
Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer.
PMID 42747633 — breast neoplasms, neoplasms, phenotype, neoplasm metastasis, breast		Breast Cancer Res Treat20260
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.
PMID 41941252 — triple negative breast neoplasms, breast neoplasms, neoplasms, biomarkers, breast, therapeutics, mutation, trastuzumab, her2 mutation		Clin Cancer Res20264
Economic value of ribociclib in early breast cancer in the United States.
PMID 42504809 — breast neoplasms, neoplasms, breast, quality-adjusted life years, therapeutics		J Manag Care Spec Pharm20260

Clinical Studies 51

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 3 29
N/A 11
Phase 2 9
Phase 1 1
Phase 2/Phase 3 1

By status:

Completed 34
Active not recruiting 9
Recruiting 4
Terminated 2
Unknown 2

By type:

Interventional 42
Observational 9

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 2
multicentric5to9 1
multicentricup10 40

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Real life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
NCT06495164 — anastrozole, aromatase, aromatase inhibitors, breast neoplasms, pharmaceutical preparations, neoplasms, letrozole, breast, therapeutics		N/AActive not recruiting2024
Neoadjuvant Neratinib in Stage I III HER2 Mutated Lobular Breast Cancers
NCT05919108 — cells, mastectomy, blood, breast neoplasms, neoplasms, magnetic resonance imaging, mastectomy, segmental, biopsy, breast, work, therapeutics, carcinoma, lobular, mouth, carcinoma		Phase 2Recruiting2024
Shorter Chemo Immunotherapy Without Anthracycline Drugs for Early Stage Triple Negative Breast Cancer
NCT05929768 — taxes, injections, cells, quality of life, triple negative breast neoplasms, growth, blood, breast neoplasms, docetaxel, paclitaxel, pharmaceutical preparations, surgical procedures, operative, cyclophosphamide, doxorubicin, neoplasms, drug therapy, immunotherapy, breast, work, daunorubicin, anthracyclines, specimen handling, therapeutics, carboplatin, dna, chemotherapy, carcinoma		Phase 3Recruiting2023
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors The ComboMATCH Screening Trial
NCT05564377 — leucovorin, taxes, research design, fulvestrant, phosphoinositide-3 kinase inhibitors, uracil, genetic testing, genitalia, female, poly(adp-ribose) polymerase inhibitors, bone marrow, blood, breast neoplasms, paclitaxel, radionuclide angiography, tomography, heart, fallopian tube neoplasms, positron-emission tomography, ovary, neoplasms, multiple chronic conditions, gated blood-pool imaging, magnetic resonance imaging, phosphatidylinositol 3-kinase, angiography, biopsy, oxaliplatin, phosphatidylinositols, fluorouracil, neoplasm metastasis, ovarian neoplasms, breast, echocardiography, antibodies, monoclonal, specimen handling, panitumumab, therapeutics, clone cells, mutation, radionuclide ventriculography, fallopian tubes, endometrial neoplasms, radionuclide imaging, carcinoma, female, bone and bones		Phase 2Recruiting2023
Study of Sacituzumab Govitecan hziy and Pembrolizumab Versus Treatment of Physician s Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer
NCT05382286 — albumin-bound paclitaxel, triple negative breast neoplasms, breast neoplasms, paclitaxel, neoplasms, breast, therapeutics, carboplatin		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS